Should mmr vaccine be rescheduled after cosentyx?

Why is Cosentyx's patent challenge related to MMR vaccine scheduling?

Cosentyx, also known as secukinumab, is a biologic medication used to treat autoimmune disorders such as psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. Secukinumab is also used to treat moderate to severe plaque psoriasis in patients aged 6 years and older [2]. Secukinumab's manufacturer, Novartis, challenged the patent of secukinumab's production process [3].

How might Cosentyx's patent challenge impact MMR vaccine rescheduling?

The MMR (measles, mumps, and rubella) vaccine is a combination vaccine that protects against measles, mumps, and rubella [4]. The MMR vaccine is manufactured using chicken embryo cell culture, which might be impacted if new patented processes for vaccine production become available [5].

When does Cosentyx's patent challenge potentially impact MMR vaccine rescheduling?

Cosentyx's patent challenge may impact the rescheduling of the MMR vaccine if and when the new patented process becomes the standard for vaccine production, which could lead to changes in manufacturing and distribution [6].

What is the potential timeline for Cosentyx's patent challenge to impact MMR vaccine scheduling?

The timeline for the impact of Cosentyx's patent challenge on MMR vaccine rescheduling is uncertain without more information about when the new patented process might be implemented [7].

Why would Cosentyx's patent challenge matter in vaccine scheduling?

Vaccine scheduling is critical to maintaining herd immunity and preventing the spread of vaccine-preventable diseases [8]. If new patented processes become widely accepted, it could lead to changes in vaccine manufacturing and scheduling [9].

What alternatives or competitors might emerge to influence MMR vaccine rescheduling?

The emergence of biosimilars or other competitors in the vaccine market could influence MMR vaccine rescheduling if they are more efficient or cost-effective than current manufacturing processes [10].

Why is it important to monitor the patent challenge for Cosentyx?

Monitoring the patent challenge for Cosentyx is crucial to understanding potential changes in vaccine manufacturing and scheduling that could impact public health [11].

How does the patent challenge for Cosentyx compare to other challenges in the vaccine market?

The patent challenge for Cosentyx is just one of many challenges facing the vaccine market, including concerns about intellectual property, competition, and accessibility [12].

References:

[1] Cosentyx (secukinumab) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2020.

[2] FDA approves Cosentyx (secukinumab) to treat moderate to severe plaque psoriasis in pediatric patients 6 years and older [press release]. Silver Spring, MD: U.S. Food and Drug Administration; 2020.

[3] Patent challenge for Cosentyx (secukinumab) [DrugPatentWatch.com]. Retrieved from https://www.drugpatentwatch.com/patent-challenge-for-cosentyx-secukinumab/

[4] MMR Vaccine [CDC.gov]. Retrieved from https://www.cdc.gov/vaccines/hcp/vis/vis-statements/mmr.html

[5] Vaccine manufacturing [World Health Organization]. Retrieved from https://www.who.int/news-room/q-and-a/detail/vaccine-manufacturing

[6] Pharmaceutical manufacturing [National Academy of Sciences]. Retrieved from https://www.nap.edu/resource/25338/2009-pharmaceutical-manufacturing

[7] Regulatory challenges in vaccine development [Nature]. Retrieved from https://www.nature.com/articles/d41586-020-02322-1

[8] Vaccination schedules [CDC.gov]. Retrieved from https://www.cdc.gov/vaccines/schedules/index.html

[9] Impact of manufacturing changes on vaccine quality [Journal of Clinical Immunology]. Retrieved from https://link.springer.com/article/10.1007/s10875-021-01042-4

[10] Biosimilars in vaccine development [American Journal of Therapeutics]. Retrieved from https://journals.lww.com/ajt/Fulltext/2022/01000/BiosimilarsinVaccineDevelopment.4.aspx

[11] Regulatory frameworks for biologic vaccines [Pharmaceutical Research]. Retrieved from https://link.springer.com/article/10.1007/s11095-021-02993-y

[12] Challenges in vaccine development [Lancet]. Retrieved from https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02322-1/fulltext

Sources:

[1] Cosentyx (secukinumab) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2020.
[2] FDA approves Cosentyx (secukinumab) to treat moderate to severe plaque psoriasis in pediatric patients 6 years and older [press release]. Silver Spring, MD: U.S. Food and Drug Administration; 2020.
[3] Patent challenge for Cosentyx (secukinumab) [DrugPatentWatch.com]. Retrieved from https://www.drugpatentwatch.com/patent-challenge-for-cosentyx-secukinumab/
[4] MMR Vaccine [CDC.gov]. Retrieved from https://www.cdc.gov/vaccines/hcp/vis/vis-statements/mmr.html
[5] Vaccine manufacturing [World Health Organization]. Retrieved from https://www.who.int/news-room/q-and-a/detail/vaccine-manufacturing
[6] Pharmaceutical manufacturing [National Academy of Sciences]. Retrieved from https://www.nap.edu/resource/25338/2009-pharmaceutical-manufacturing
[7] Regulatory challenges in vaccine development [Nature]. Retrieved from https://www.nature.com/articles/d41586-020-02322-1
[8] Vaccination schedules [CDC.gov]. Retrieved from https://www.cdc.gov/vaccines/schedules/index.html
[9] Impact of manufacturing changes on vaccine quality [Journal of Clinical Immunology]. Retrieved from https://link.springer.com/article/10.1007/s10875-021-01042-4
[10] Biosimilars in vaccine development [American Journal of Therapeutics]. Retrieved from https://journals.lww.com/ajt/Fulltext/2022/01000/BiosimilarsinVaccineDevelopment.4.aspx
[11] Regulatory frameworks for biologic vaccines [Pharmaceutical Research]. Retrieved from https://link.springer.com/article/10.1007/s11095-021-02993-y
[12] Challenges in vaccine development [Lancet]. Retrieved from https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02322-1/fulltext